Introduction
'It may seem strange that a man of science should believe a thing of this kind -an idle tale for the ignorant and superstitious, you will say -but I do believe it. And if you would know why, listen' (W.H.C. Pynchon)
Cancer is second only to heart disease as a cause of death in developed countries. Treatment hinges on effective surgical removal of the primary tumour, but cancer returns in many patients. Even with the best technique, tumour surgery is usually associated with release of tumour cells into the lymphatic and blood streams; furthermore, many patients already harbour micrometastases and scattered tumour cells at the time of surgery (Denis et al., 1997) . Whether this 'minimal residual disease' results in clinical metastases depends largely on the balance between antimetastatic immune activity and the tumour's ability to seed, proliferate, and attract new blood vessels (Smyth et al., 2001; Shakhar and Ben-Eliyahu, 2003) . In practice, the immune system and other host defences frequently fail to neutralize minimal residual disease; consequently, local recurrence and metastatic disease remain common after breast cancer surgery.
Surgery with general anaesthesia promotes cancer recurrence
At least three perioperative factors impair host defence against minimal residual disease. The first is surgery per se, which releases tumour cells into circulation (Denis et al., 1997) , depresses cell-mediated immunity including cytotoxic T cell and natural killer (NK) cell functions (Wong et al., 1999; Bar-Yosef et al., 2001) , reduces circulating concentrations of tumour-related antiangiogenic factors (e.g. angiostatin and endostatin) (O'Reilly et al., 1997; Zetter, 1998) , increases concentrations of proangiogenic factors such as vascular endothelial growth factor (Antoni et al., 2006) , and releases growth factors that promote local and distant growth of malignant tissue (Shakhar and Ben-Eliyahu, 2003) . The second factor is general anaesthesia, which impairs numerous immune functions, including neutrophil, macrophage, dendritic cell, T cell, and NK cell functions (Brand et al., 1997; Sacerdote et al., 2000) . The third factor is the use of opioids, which are given to control surgical pain. Opioids inhibit both cellular and humoral immune function in humans (Beilin et al., 1996; Sacerdote et al., 2000) . Furthermore, morphine is proangiogenic and promotes breast tumour growth in rodents (Gupta et al., 2002) . Consequently, nonopioid analgesia helps preserve NK cell function in animals and humans, and reduces metastatic spread of cancer in rodents (Ben-Eliyahu et al., 1999) .
Regional anaesthesia and analgesia may be protective
Regional anaesthesia (intraoperative blockade of nociception) and analgesia (postoperative pain relief) attenuate or prevent the tumour-promoting effects of general anaesthesia and opioid analgesia. For example, regional anaesthesia largely prevents the neuroendocrine stress response to surgery by keeping afferent neural transmission from reaching the central nervous system and activating the stress response, and by blocking descending efferent activation of the sympathetic nervous system (Buggy and Smith, 1999; O'Riain et al., 2005) . As might therefore be expected, regional anaesthesia better attenuates surgical stress than does general anaesthesia. Consequently, NK cell function is better preserved and metastatic load to the lungs is reduced by neuraxial anaesthesia in a rat model of breast cancer metastasis (Bar-Yosef et al., 2001; Wada et al., 2007) .
When regional and general anaesthesia are combined, the amount of general anaesthetic required is greatly reduced -as is, presumably, immune suppression. Furthermore, regional analgesia provides superb pain relief, essentially obviating the need for postoperative opioids and the consequent adverse effects on immune function and promotion of tumour growth (Sacerdote et al., 2000; O'Riain et al., 2005) . Regional analgesia also reduces release of endogenous opioids (Chae et al., 1998) .
Observational data in humans also support a protective effect of regional anaesthesia and analgesia: 50 women having mastectomies with paravertebral anaesthesia and analgesia combined with general anaesthesia were compared with 79 patients having the same operation under general anaesthesia combined with postoperative morphine analgesia (Exadaktylos et al., 2006) . No significant differences in patient characteristics, surgical details, tumour presentation, or prognostic factors between the groups were observed. Nonetheless, recurrence and metastasis-free survival was 94% (95% confidence interval: 87, 100) in the paravertebral group versus only 77% (95% confidence interval: 68, 87) in the general anaesthesia patients at 36 months (P = 0.013).
Additional retrospective support is provided by the observation that melanoma recurrence is 40% more likely in patients given general anaesthesia than local anaesthesia (Schlagenhauff et al., 2000) . Both the breast cancer (Exadaktylos et al., 2006) and melanoma (Schlagenhauff et al., 2000) studies used multivariate techniques to compensate for major prognostic factors; but given the numerous and serious limitations of retrospective analyses, the results should be considered suggestive rather than confirmatory.
Hypothesis
Available data suggest that regional anaesthesia and analgesia help preserve effective defences against tumour progression by attenuating the surgical stress response, by reducing general anaesthesia requirements, and by sparing postoperative opioids (Fig. 1) . I thus offer the hypothesis that local and metastatic recurrence of cancer is reduced when patients receive intraoperative and postoperative regional analgesia rather than intraoperative general anaesthesia and postoperative opioid analgesia.
Testing the hypothesis
My hypothesis is testable, but doing so would require a major, multicentre trial, and given the delay between enrolment and recurrence, the study could take nearly a decade. The putative benefits of regional anaesthesia should apply to most or any type of cancer suitable for neuraxial or peripheral nerve blocks. For study purposes, however, it should be a type with an intermediate prognosis and reasonably rapid growth. For example, ovarian cancer is frequently disseminated at the time of diagnosis and the prognosis is so poor that it might mask true benefits of regional anaesthesia. Conversely, prostatic cancer is slow-growing, which would lengthen the required postoperative observation time. Colon cancer would be an ideal tumour to test (roughly 30% recurrence, usually within 2 years); but perhaps the most obvious candidate is breast cancer as preliminary data are already available for this tumour and either paravertebral or thoracic epidural anaesthesia can be used.
Enrolment would have to be restricted to patients who agree to randomized assignment to (i) regional anaesthesia and analgesia with sedation or a 'light' general anaesthetic, or (ii) full general anaesthesia with opioid analgesia. Although it might seem unlikely that patients would accept such a randomization, earlier large studies have randomized patients to regional versus general anaesthesia to evaluate other outcomes. Patients can be at least partially masked by using sham regional anaesthesia. Operating room staff cannot be blinded, but investigators who are completely unaware of intraoperative management, that is, blinded, can conduct follow-ups.
Patients and their physicians should be contacted at regular intervals to evaluate the primary outcome, which would be either local or metastatic cancer recurrence. The primary statistical technique should be a KaplanMeier analysis with log-rank test, stratified by centre, and based on intention-to-treat. Secondary multivariable analysis can include Cox proportional hazards regression to adjust the treatment effect for clinical centre and other baseline factors found to be associated with cancer recurrence. This should include time-varying covariates, including chemotherapy or radiotherapy, which the patient receives after surgery, but before recurrence.
The number of patients required would depend on numerous factors including the recurrence rate, enrolment rate, and follow-up period. As an example, consider breast cancer, and assume a distribution of tumour stage and pattern of recurrence similar to that observed in the summary of trials reported by Saphner et al. (1996) Further, assume that patients would be enroled over a 5-year period, with three interim analyses, a 3% dropout rate per year, and an a of 0.05. Under these circumstances, up to 2700 patients would be required to provide a 90% power for detecting a 20% benefit; alternatively, up to 1100 patients would be required to provide an 85% power for detecting a 30% treatment effect. Assuming the trial was not stopped early for efficacy or futility, the duration (including follow-up) would be about 8 years. A trial powered for either treatment effect would be a formidable and prolonged mission, but perfectly possible.
Clinical implications
Confirming the hypothesis that regional analgesia for cancer surgery reduces the risk of recurrence would be immediately applicable as regional blocks are routine procedures that are familiar to most anaesthesiologists. A minor modification to anaesthetic management -one that can be implemented with little risk or cost -might thus reduce the risk of metastases, a complication that is ultimately lethal in most patients. Cancer surgery is usually performed under general anaesthesia with postoperative analgesia provided by opioids. The stress of surgery, general anaesthetics, and opioid analgesics are each immunosuppressive and specifically inhibit cell-mediated immunity that is critical for control of minimal residual disease. Opioids and stress also increase angiogenesis, which promotes growth of cancer cells. Regional anaesthesia and analgesia may reduce the risk of cancer recurrence because it blocks the neuroendocrine stress response, decreases or eliminates the need for general anaesthetics, and obviates the need for postoperative opioids.
